Positron-Emission Tomography Clinical Trial
Official title:
The Diagnostic Value of 18F-FET PET/MRI for CNS Tumors in Children and Adolescents
To investigate the diagnostic value of 18F-FET PET/MRI instead of MRI alone, children and adolescents with tumor in brain or spinal cord are included and scanned primarily at our hybrid PET/MRI using the amino acid analog 18F-FET. The scans are performed at primary diagnosis, before radiation therapy, before and after operation, when relapse is suspected and three or six months after initiation of chemotherapy.
Background. Tumors in the brain and spinal cord are among the most common causes of death and
disability by cancer in children and adolescents. MRI is used for primary diagnosis as well
as follow-up but is often challenged by tissue changes caused by the treatment. The amino
acid analog 18F-FET is used increasingly in adults to delineate tumor and discriminate tumor
from treatment effects. A hybrid PET/MRI scanner enables the simultaneous imaging with PET
and MRI, which is important in especially the younger children needing anaesthesia to
cooperate to the procedure.
Aim The aim of the study is to compare diagnostics using MRI alone with 18F-FET PET/MRI (or
sequential MRI and PET) in children and adolescents diagnosed with a central nervous system
(CNS) tumor before the age of 18 years. The scans will be performed at primary
diagnosis/before operation/biopsy, within 72 hours after operation, planning radiation
therapy, evaluation of treatment effect, when relapse is suspected.
Exclusion criteria are MRI contraindications, pregnancy, or a syndrome with increased
sensitivity to radiation.
The investigators wish to evaluate which cases and for which tumor types, 18F-FET PET/MRI
will increase sensitivity and specificity of diagnosing CNS tumors.
Side effects The side effects are mainly the side effect from the MRI with venous puncture,
the MRI contrast leading that can lead to shortlived nausea or headache, fasting for 6 hours
and the radioactivity exposure of 4.2 mSv (1,4 times the early background radiation) for each
scan procedure. The maximal number of scans in the project is 3, 6 or 10 depending on the
diagnosis.
Data Analysis The correlation between 18F-FET uptake in tumor and tumor grading (obtained
from operation/biopsy) will be investigated.
When relapse is suspected, sensitivity and specificity for recurrence/progression for MRI
alone versus PET/MRI will be compared.
It will be analysed if the addition of PET influences the diagnosis/chosen treatment. A major
impact of 6% will be regarded significant.
The prognostic value of 18F-FET uptake after treatment will be investigated.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04555642 -
Early Diagnosis of Therapy-associated Cardiotoxicity Basing on Multi-tracer Multimodality PET/MRI
|
||
Recruiting |
NCT05004961 -
The Performance of Multi-tracer Multimodality PET in Lymphoma
|
||
Recruiting |
NCT05188872 -
Application of 68Ga-Pentixafor PET/CT in Primary Aldosteronism and Pre-postoperative of SAAE
|
N/A | |
Recruiting |
NCT04983095 -
Metastasis Directed Stereotactic Body Radiotherapy for Oligo Metastatic Hormone Sensitive Prostate Cancer
|
Phase 3 | |
Recruiting |
NCT05610098 -
Gene Expression Profiles in Spinal Tuberculosis.
|
||
Recruiting |
NCT04416165 -
Comparison of FDG and FAPI in Patients With Various Types of Cancer
|
N/A | |
Recruiting |
NCT04750772 -
Positron Nuclide Labeled DOTA-FAPI PET Study in Colocrectal Cancer
|
N/A | |
Recruiting |
NCT04831541 -
68Ga-PSMA-11 PET/CT in Patients With Various Types of Cancer
|
Early Phase 1 | |
Recruiting |
NCT06017973 -
The Role of Imaging in the Diagnosis, Management and Prognosis of Possible Non-convulsive Status Epilepticus
|
N/A | |
Recruiting |
NCT06188468 -
ImmunoPET Targeting Trophoblast Cell-surface Antigen 2 (Trop-2) in Solid Tumors
|
N/A | |
Recruiting |
NCT03830242 -
Diagnostic Significance of FDG PET/CT Dynamic Imaging in Detecting Metastatic Lymph Nodes With Papillary Thyroid Cancer.
|
N/A | |
Recruiting |
NCT06387381 -
68Ga-PSFA PET Imaging in Patients With PSMA/FAP Positive Disease
|
Early Phase 1 | |
Recruiting |
NCT05506566 -
68Ga-FAP-CHX PET/CT : Dosimetry and Preliminary Clinical Translational Studies
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT04367948 -
Positron Nuclide Labeled NOTA-FAPI PET Study in Lymphoma
|
N/A | |
Recruiting |
NCT05757804 -
Study of 18F-0502B PET Imaging Targeting α-synuclein in the Diagnosis of α-synuclein-related Diseases
|
||
Completed |
NCT05392205 -
Comaprison of 68Ga-FAP-2286 and 18F-FDG PET/CT in Patients With Various Types of Cancer
|
N/A | |
Completed |
NCT03741231 -
18FDG-PET in Patients With Melanoma or NSCLC Treated With Immunotherapy
|
||
Completed |
NCT01035164 -
Evaluation of ZK 6032924 in Probable Alzheimer's Disease Patients Versus Healthy Volunteers and the Radiation Dosimetry of ZK 6032924 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT03107663 -
⁸⁹Zr-Df-IAB22M2C PET/CT in Patients With Selected Solid Malignancies or Hodgkin's Lymphoma
|
Phase 1 | |
Recruiting |
NCT03636607 -
Diagnostic Significance of Single Center, Open and Prospective Evaluation of <Sup>18<Sup>F-FDG PET/CT Dynamic Imaging and Genomic Sequencing in Detecting Metastatic Lesions of Primary Hepatocellular Carcinoma
|
N/A |